Common Contracts

Contract

Transition Agreement • May 5th, 2020 • New York

• Contract Type
  Transition Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  New York

EX-10.4 5 ex104.htm EXHIBIT 10.4 Exhibit 10.4 EXECUTION VERSION STRICTLY CONFIDENTIAL TRANSITION AGREEMENT THIS TRANSITION AGREEMENT, dated as of March 2, 2015 (together with all Schedules and Exhibits attached hereto, this “Agreement”), is by and between Novartis Pharma AG, a Swiss corporation (“Novartis”), and Array BioPharma Inc., a Delaware corporation (“Array”). Novartis and Array are sometimes collectively referred to herein as the “Parties” and each separately as a “Party.” WHEREAS, Novartis and Array are parties to the Termination and Asset Transfer Agreement dated as of November 26, 2014 (the “Termination Agreement”); and WHEREAS, in connection with the Contemplated Transactions, the Parties desire to provide for the transition of certain activities related to the Development of Binimetinib from Novartis to Array (the “Transition”), on the terms and subject to the conditions hereof. NOW, THEREFORE, in consideration of the foregoing and the mutual agreements and covenants herei

TRANSITION AGREEMENT

Transition Agreement • May 7th, 2015 • Array Biopharma Inc • Pharmaceutical preparations • New York

• Contract Type
  Transition Agreement
• Filed
  May 7th, 2015
• Company
  Array Biopharma Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

[*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information.